ArticleJournal of clinical medicine2020
Concomitant
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 68 citations in OpenAlex.
- EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study.Cancer research and treatment · 2023Trial
- Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Cancer cell · 2022Trial
- Trial
- Early-Phase Activation of Epithelial-Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.International journal of molecular sciences · 2026Article
- Predicting primary resistance to third-generation EGFR-TKIs in lung adenocarcinoma using a multisource cross-modal transformer model.NPJ precision oncology · 2026Article
- TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.Journal of clinical medicine · 2026Article
- The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy.Discover oncology · 2026Article
- Prognostic value of baselineFrontiers in nuclear medicine · 2026Article
- Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.JCO precision oncology · 2025Article
- Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboringGlobal medical genetics · 2025Article
- EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2025Article
- Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study.Therapeutic advances in medical oncology · 2025Article
- Article
- Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report.Oncology letters · 2024Article
- Article
- TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.NPJ precision oncology · 2024Article
- Concordance of Abundance for MutationalCurrent oncology (Toronto, Ont.) · 2023Article
- Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer withTranslational lung cancer research · 2023Article
- Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Thoracic cancer · 2023Article
- The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor (
methodsAn independent retrospective cohort study was conducted, on a case series of 136
resultsForty-two patients (30.9%) showed a
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.